ClinicalTrials.gg
CompletedNCT01585324Updated Jul 24, 2015Results posted

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and ribavirin [Copegus] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 1 site in Czech Republic. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
71st of 83
30 · median 129
Started
2012
with 6 others
Phase 4
48 of 83
none open now
Registered
69th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 71st largest by enrollment, is one of 7 that started in 2012, is one of 48 in phase 4, and was the 69th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a). Patients will receive Copegus 1000 mg or 1200 mg orally daily and Pegasys 180 mcg subcutaneously weekly. Anticipated time on study treatment, depending on virological response, will be 48 or 72 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Chronic , genotype 1
  • Treatment-naïve or patients who or failed to respond to previous combination therapy with interferon and ribavirin
  • Detectable HCV-RNA
  • Fertile males and females of must agree to use two forms of during treatment and for 6 months after treatment end

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Male partners of pregnant women
  • History or evidence of a medical condition associated with chronic liver disease other than
  • Co-infection with active hepatitis A, and/or virus
  • Hepatocellular carcinoma
  • History or evidence of oesophageal varices or other conditions consistent with decompensated liver disease
  • Anemia
  • Any patient with increased baseline risk for anemia (e.g. thalassemia, spherocyctosis, history of GI bleeding)
  • History or evidence of significant cardiovascular disease
  • Kidney disease
  • Severe retinopathy
  • History of severe psychiatric disease, especially depression
  • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of and radiation) \</= 6 months prior to first dose of study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment

    SVR was defined as a disappearance of HCV viral load 24 weeks after the end of the treatment.

    Time frame: 24 weeks after the end of treatment (72 weeks)

  2. Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR

    Change in hemoglobin level from a baseline level was assessed in the group of participants who achieved SVR and in the group of participants without SVR.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants With Decrease in Hemoglobin

    The drop in hemoglobin level at Week 12 compared to level at baseline was assessed and categorized in pre-defined categories (up to 20, 20-40, greater than \[\>\] 40 g/L) for the group of participants who achieved SVR and in the group of participants without SVR.

    Time frame: Week 12

  2. Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR

    The mean minimum hemoglobin value achieved during the treatment was assessed in the group of participants who achieved SVR and in the group of participants without SVR.

    Time frame: Week 12

  3. Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR

    Time frame: Week 12

  4. Number of Participants With Neutropenia Among Participants With or Without SVR

    Time frame: Week 12

  5. Number of Participants With Thrombocytopenia Among Participants With or Without SVR

    Time frame: Week 12

07

Results

Posted Jul 24, 2015

Participant flow

Participant flow — Overall Study
MilestonePeginterferon Alpha-2a + Ribavirin
Started30
Completed30
Not completed0

Outcome measures

PrimaryPercentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment

SVR was defined as a disappearance of HCV viral load 24 weeks after the end of the treatment.

Time frame:
24 weeks after the end of treatment (72 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment
percentage of participantsPeginterferon Alpha-2a + Ribavirin
Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment83.3 (65.28 to 94.36)
Statistical analysis
  • Peginterferon Alpha-2a + Ribavirin · ANCOVA · p = 0.8333The analysis of covariance (ANCOVA) test for the efficacy of SVR achievement (Yes/No), treatment adjustment and baseline hemoglobin value was used.
PrimaryChange From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR

Change in hemoglobin level from a baseline level was assessed in the group of participants who achieved SVR and in the group of participants without SVR.

Time frame:
Baseline and Week 12
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR
grams per liter (g/L)Participants With SVRParticipants Without SVR
Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR-23.0 ± 14.768-32.4 ± 11.502
SecondaryNumber of Participants With Decrease in Hemoglobin

The drop in hemoglobin level at Week 12 compared to level at baseline was assessed and categorized in pre-defined categories (up to 20, 20-40, greater than \[\>\] 40 g/L) for the group of participants who achieved SVR and in the group of participants without SVR.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Decrease in Hemoglobin
participantsParticipants With SVRParticipants Without SVR
Up to 20 g/L90
20-40 g/L143
>40 g/L22
Statistical analysis
  • Participants With SVR vs Participants Without SVR · Fisher Exact · p = 0.0867
SecondaryLowest Hemoglobin Level During Treatment Among Participants With or Without SVR

The mean minimum hemoglobin value achieved during the treatment was assessed in the group of participants who achieved SVR and in the group of participants without SVR.

Time frame:
Week 12
Reported as:
Mean · g/L
Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR
g/LParticipants With SVRParticipants Without SVR
Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR124.24 ± 10.080126.60 ± 10.383
SecondaryNumber of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR
Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR
participantsParticipants With SVRParticipants Without SVR
Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR10
Statistical analysis
  • Participants With SVR vs Participants Without SVR · ANCOVA · p = 0.6492
SecondaryNumber of Participants With Neutropenia Among Participants With or Without SVR
Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Neutropenia Among Participants With or Without SVR
participantsParticipants With SVRParticipants Without SVR
Number of Participants With Neutropenia Among Participants With or Without SVR00
SecondaryNumber of Participants With Thrombocytopenia Among Participants With or Without SVR
Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Thrombocytopenia Among Participants With or Without SVR
participantsParticipants With SVRParticipants Without SVR
Number of Participants With Thrombocytopenia Among Participants With or Without SVR10
Statistical analysis
  • Participants With SVR vs Participants Without SVR · Wilcoxon (Mann-Whitney) · p = 0.0333

Adverse events

Collected over From baseline up to 24 weeks after end of treatment (up to 72 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alpha-2a + Ribavirin—0/30 (0%)19/30 (63.3%)
Most frequent other events
Most frequent other events
EventPeginterferon Alpha-2a + Ribavirin
Influenza like illnessGeneral disorders14/30
FatigueGeneral disorders5/30

Baseline characteristics

Intent-to-treat (ITT) analysis population included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Peginterferon Alpha-2a + Ribavirin
Mean32.1 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alpha-2a + Ribavirin
Female1
Male29
08

Study locations

1 site
  • Most, 43401, Czech Republic
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2012
First posted
Apr 25, 2012
Start
Jan 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Jul 24, 2015
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01585324
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 25, 2012
Start date
Jan 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Jul 24, 2015
Last update
Jul 24, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion